Association of body composition and systemic inflammation for patients with locally advanced cervical cancer following concurrent chemoradiotherapy

被引:0
|
作者
Li, Juan [1 ]
Niu, Cuili [1 ]
Zhang, Ling [1 ]
Mu, Yanmin [1 ]
Gui, Xiuyin [1 ]
机构
[1] Xingtai Third Hosp, Clin Gynecol, Xingtai, Peoples R China
来源
DIAGNOSTIC AND INTERVENTIONAL RADIOLOGY | 2024年 / 30卷 / 05期
关键词
Cervical cancer; concurrent chemoradiotherapy; systemic inflammation; body composition; prognosis; VISCERAL FAT PERCENTAGE; PROGNOSTIC VALUE; SARCOPENIA; OBESITY; PREDICTION; MARKERS; CELLS;
D O I
10.4274/dir.2024.242751
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
PURPOSE Systemic inflammation and body composition are associated with survival outcomes of cancer patients. This study aimed to examine the combined prognostic value of systemic inflammatory markers and body composition parameters in patients with locally advanced cervical cancer (LACC). METHODS Patients who underwent concurrent chemoradiotherapy (CCRT) for LACC at a tertiary referral teaching hospital between January 2010 and January 2018 were enrolled. A predictive model was established based on systemic immune-inflammation index (SII) and computer tomography-derived visceral fat-to-muscle ratio (vFMR). Overall survival (OS) and progression-free survival (PFS) were assessed using the Kaplan-Meier method and Cox regression models. The model performance was assessed using discrimination, calibration, and clinical usefulness. RESULTS In total, 212 patients were enrolled. The SII and vFMR were closely related, and both independently predicted survival (P < 0.05). A predictive model was established based on the above biomarkers and included three subgroups: high-risk [both high SII (>828) and high vFMR (>1.1)], middle-risk (either high SII or high vFMR), and low-risk (neither high SII nor high vFMR). The 3-year OS (PFS) rates for low-, middle-, and high-risk patients were 90.5% (86.0%), 73.9% (58.4%), and 46.8% (36.1%), respectively (P < 0.05). This model demonstrated satisfactory predictive accuracy (area under the curve values for predicting 3-year OS and PFS were 0.704 and 0.718, respectively), good fit (Hosmer-Lemeshow tests: P > 0.05), and clinical usefulness. CONCLUSION Systemic inflammatory markers combined with body composition parameters could independently predict the prognosis of patients with LACC, highlighting the utilization of commonly collected indicators in decision-making processes.
引用
收藏
页码:279 / 290
页数:12
相关论文
共 50 条
  • [21] Longitudinal dynamic MRI radiomic models for early prediction of prognosis in locally advanced cervical cancer treated with concurrent chemoradiotherapy
    Cai, Chang
    Xiao, Ji-Feng
    Cai, Rong
    Ou, Dan
    Wang, Yi-Wei
    Chen, Jia-Yi
    Xu, Hao-Ping
    RADIATION ONCOLOGY, 2024, 19 (01)
  • [22] Concurrent chemoradiotherapy combined with immunotherapy is superior to traditional concurrent chemoradiotherapy in the treatment of advanced cervical cancer
    Peng, Hsiu-Huei
    Wang, Yi-Lun
    Lin, Cheng-Tao
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2019, 40 (01) : 36 - 39
  • [23] Analysis of Treatment Outcomes and Prognosis After Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer
    Peng, Qing-he
    Chen, Kai
    Li, Jun-yun
    Chen, Li
    Ye, Wei-jun
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [24] Comparison of Nedaplatin- and Cisplatin-Based Concurrent Chemoradiotherapy in Locally Advanced Cervical Cancer Patients: A Propensity Score Analysis
    Li, Ping
    Zhang, Rui
    Nie, Zhihua
    Long, Mengjuan
    Zhang, Gong
    Fu, Zhenming
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 (05) : 1029 - 1037
  • [25] Optimal cisplatin cycles in locally advanced cervical carcinoma patients treated with concurrent chemoradiotherapy
    Zeng, Zheng
    Wang, Weiping
    Liu, Xiaoliang
    Wang, Guangyu
    Ren, Kang
    Zhang, Fuquan
    Hu, Ke
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2023, 25 (10): : 2892 - 2900
  • [26] Optimal cisplatin cycles in locally advanced cervical carcinoma patients treated with concurrent chemoradiotherapy
    Zheng Zeng
    Weiping Wang
    Xiaoliang Liu
    Guangyu Wang
    Kang Ren
    Fuquan Zhang
    Ke Hu
    Clinical and Translational Oncology, 2023, 25 : 2892 - 2900
  • [27] Pretreatment lymphocyte count as independent prognostic factor in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy
    Thiangphak, Ekasak
    Pruegsanusak, Korrawit
    Buhachat, Rakchai
    INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2022, 159 (03) : 672 - 678
  • [28] The relationship between tumour stage, systemic inflammation, body composition and survival in patients with colorectal cancer
    McSorley, Stephen T.
    Black, Douglas H.
    Horgan, Paul G.
    McMillan, Donald C.
    CLINICAL NUTRITION, 2018, 37 (04) : 1279 - 1285
  • [29] The prognostic value of the combination of body composition and systemic inflammation in patients with cancer cachexia
    Xie, Hai-Lun
    Ruan, Guo-Tian
    Wei, Lishuang
    Zhang, Qi
    Ge, Yi-Zhong
    Song, Meng-Meng
    Zhang, Xi
    Lin, Shi-qi
    Liu, Xiao-yue
    Zhang, Xiao-Wei
    Li, Xiang-Rui
    Zhang, Kang-Ping
    Hu, Chun-Lei
    Yang, Ming
    Tang, Meng
    Song, Chun-Hua
    Cong, Ming-Hua
    Weng, Min
    Li, Zeng-Ning
    Li, Wei
    Wang, Kun-Hua
    Shi, Han-Ping
    JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE, 2023, 14 (02) : 879 - 890
  • [30] Why Is Surgery Still Done after Concurrent Chemoradiotherapy in Locally Advanced Cervical Cancer in Romania?
    Voinea, Silviu Cristian
    Bordea, Cristian Ioan
    Chitoran, Elena
    Rotaru, Vlad
    Andrei, Razvan Ioan
    Ionescu, Sinziana-Octavia
    Luca, Dan
    Savu, Nicolae Mircea
    Capsa, Cristina Mirela
    Alecu, Mihnea
    Simion, Laurentiu
    CANCERS, 2024, 16 (02)